Donate

The following is information from the U.S. Food and Drug Administration. Read the full press release here.


The U.S. Food and Drug Administration (FDA) advises health care professionals not to use ChloraPrep 3 mL applicators manufactured by Becton, Dickinson and Company (BD) due to microbial contamination risks. The drug was distributed globally and is labeled with 鈥淐areFusion, El Paso, TX.鈥

BD鈥檚 investigation confirmed the product鈥檚 lid, when exposed to higher temperature and humidity, can fail and lead to microbial contamination which may cause serious infections, especially in patients with compromised immune systems.

This drug is used to sanitize skin prior to surgery or catheter procedures. Health care professionals should use an available alternative.

FDA recommended on March 15, 2021, that BD expand their recall (initiated in June 2020) to include all unexpired ChloraPrep 3 mL applicators in the U.S. The company鈥檚 limited recall, which covered countries and U.S. territories with tropical climates, was due to the lid defect after a finding of fungal growth that breached the product seal. To date, the company has not taken action to expand their recall and remove additional dangerous drugs from the U.S. market.

FDA is not aware of any adverse events associated with use of BD鈥檚 ChloraPrep 3 mL applicators. FDA encourages health care professionals and patients to report adverse events or quality problems experienced with the use of any medication to FDA鈥檚聽MedWatch Adverse Event Reporting聽program:

  • Complete and submit the report聽online; or
  • Download and complete the聽form, then submit it via fax at 1-800-FDA-0178

Sign up for E-mails, Dateline Magazine, and other ways to stay connected.